OCT in Retinal Vein Occlusions



Status:Recruiting
Conditions:Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:January 2014
End Date:December 2019
Contact:Denny Romfh
Email:romfhd@ohsu.edu
Phone:503-494-4351

Use our guide to learn which trials are right for you!

Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Retinal Vein Occlusions

Retinal blood vessel disease encompasses a wide variety of vision-threatening conditions. Of
these conditions, retinal vein occlusions are the most common. Vision loss can occur as a
result of macular ischemia (loss of blood flow to the macula) or macular edema (fluid
build-up at the macula).

OCT is an imaging technology that can perform non-contact cross-sectional imaging of retinal
and choroidal tissue structures in real time. It is similar to ultrasound imaging, except
that OCT measures the intensity of reflected light rather than sound waves.

The purpose of this study is to see if non-invasive OCT technology can changes due to retinal
vein occlusions as well as the more invasive fluorescein angiography, which requires an
injection of dye into the vein of an arm of a patient. The study will also compare the
mapping of blood vessels (angiography) and loss of blood flow (ischemia) by fluorescein
angiography and OCT. These studies will be evaluated to see how they relate to vision loss.


Inclusion Criteria:

- Diagnosis of branch or central retinal vein occlusion

Exclusion Criteria:

- Inability to give informed consent

- Inability to complete study tests within a 30 day period from date of enrollment

- Significant renal disease, defined as a history of chronic renal failure requiring
dialysis or kidney transplant

- A prior history of reaction to fluorescein or other dyes.

- A condition that, in the opinion of the investigator, would preclude participation in
the study (e.g., unstable medical status including blood pressure, cardiovascular
disease, and glycemic control).

- Blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood
pressure is brought below 180/110 by anti-hypertensive treatment, subject can become
eligible.

- Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to treatment.

- Women of child-bearing potential: pregnant or lactating or intending to become
pregnant within the next 12 months due to unknown safety of fluorescein angiography.

- Prior PRP or focal laser that would alter the macular perfusion and retino-vascular
features.

- Inability to maintain fixation for OCT imaging.

- Other ocular condition is present such that, in the opinion of the investigator, may
alter the retinal perfusion.

- An ocular condition is present that, in the opinion of the investigator, might affect
or alter visual acuity during the course of the study (e.g., cataract).

- Substantial cataract that, in the opinion of the investigator, is likely to decrease
visual acuity by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or
worse if the eye was otherwise normal).

- Media opacity or otherwise that would prevent either fixation or ability to obtain
adequate images as determined by the examiner.

- History of major ocular surgeries (including vitrectomy, cataract extraction, scleral
buckle, any intraocular surgery, etc.) within 4 months prior to enrollment.
We found this trial at
1
site
Portland, Oregon 97201
Phone: 503-494-4351
?
mi
from
Portland, OR
Click here to add this to my saved trials